Mesoblast Stock Current Asset
| MESO Stock | USD 13.68 0.14 1.03% |
Mesoblast fundamentals help investors to digest information that contributes to Mesoblast's financial success or failures. It also enables traders to predict the movement of Mesoblast Stock. The fundamental analysis module provides a way to measure Mesoblast's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mesoblast stock.
At this time, Mesoblast's Other Current Assets are very stable compared to the past year. As of the 20th of March 2025, Total Current Assets is likely to grow to about 116.5 M, while Non Current Assets Total are likely to drop about 466.6 M. Mesoblast | Current Asset |
Mesoblast Company Current Asset Analysis
Mesoblast's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Mesoblast Current Asset | 88.82 M |
Most of Mesoblast's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mesoblast is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Mesoblast Current Asset Historical Pattern
Today, most investors in Mesoblast Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Mesoblast's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Mesoblast current asset as a starting point in their analysis.
Mesoblast Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Mesoblast Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Mesoblast has a Current Asset of 88.82 M. This is 95.87% lower than that of the Biotechnology sector and 91.63% lower than that of the Health Care industry. The current asset for all United States stocks is 99.05% higher than that of the company.
Mesoblast Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mesoblast's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mesoblast could also be used in its relative valuation, which is a method of valuing Mesoblast by comparing valuation metrics of similar companies.Mesoblast is currently under evaluation in current asset category among its peers.
Mesoblast Current Valuation Drivers
We derive many important indicators used in calculating different scores of Mesoblast from analyzing Mesoblast's financial statements. These drivers represent accounts that assess Mesoblast's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Mesoblast's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 852.9M | 259.0M | 531.2M | 657.9M | 756.6M | 1.3B | |
| Enterprise Value | 821.5M | 305.8M | 576.8M | 714.3M | 821.4M | 1.2B |
Mesoblast ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mesoblast's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mesoblast's managers, analysts, and investors.Environmental | Governance | Social |
Mesoblast Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0541 | ||||
| Operating Margin | (12.49) % | ||||
| Current Valuation | 1.76 B | ||||
| Shares Outstanding | 114.18 M | ||||
| Shares Owned By Insiders | 0.07 % | ||||
| Shares Owned By Institutions | 1.38 % | ||||
| Number Of Shares Shorted | 2.26 M | ||||
| Price To Earning | (5.90) X | ||||
| Price To Book | 3.73 X | ||||
| Price To Sales | 303.27 X | ||||
| Revenue | 5.9 M | ||||
| Gross Profit | (47.42 M) | ||||
| EBITDA | (56.08 M) | ||||
| Net Income | (87.96 M) | ||||
| Cash And Equivalents | 85.5 M | ||||
| Cash Per Share | 0.62 X | ||||
| Total Debt | 118.92 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 1.90 X | ||||
| Book Value Per Share | 0.42 X | ||||
| Cash Flow From Operations | (48.46 M) | ||||
| Short Ratio | 6.69 X | ||||
| Earnings Per Share | (1.05) X | ||||
| Target Price | 14.5 | ||||
| Number Of Employees | 73 | ||||
| Beta | 2.34 | ||||
| Market Capitalization | 1.14 B | ||||
| Total Asset | 669.15 M | ||||
| Retained Earnings | (908.76 M) | ||||
| Working Capital | 13.22 M | ||||
| Current Asset | 88.82 M | ||||
| Current Liabilities | 29.41 M | ||||
| Net Asset | 669.15 M |
About Mesoblast Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mesoblast's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mesoblast using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mesoblast based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock: Check out Mesoblast Piotroski F Score and Mesoblast Altman Z Score analysis. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share | Quarterly Revenue Growth (0.41) | Return On Assets | Return On Equity |
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.